Monte Rosa Therapeutics has secured a major licensing agreement with Novartis, a global exclusive development and commercialization license agreement.
This partnership aims to advance the development of VAV1-directed molecular glue degraders (MGDs), specifically focusing on MRT-6160.
Novartis will have exclusive worldwide rights to develop, manufacture, and commercialize MRT-6160, with an upfront payment of $150 million to Monte Rosa and the potential for up to $2.1 billion in milestones.
Monte Rosa will receive tiered royalties on net sales outside the United States.
The Phase 2 clinical studies will be led by Novartis, while Monte Rosa will complete the ongoing Phase 1 clinical study.
MRT-6160 is a potent and selective oral degrader of VAV1, with potential in treating immune-mediated conditions.
Monte Rosa utilizes its QuEEN™ discovery engine, combining artificial intelligence, diverse chemical libraries, structural biology, and proteomics to identify and design MGDs.
The company has strategic alliances with Roche for cancer and neurological diseases.
Monte Rosa's innovative strategies and partnerships have the potential to reshape the therapeutic landscape in oncology, autoimmune, and inflammatory diseases.